248281-84-7 | 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$23.00	$16.00
2mg	97%	in stock	$29.00	$20.00
5mg	97%	in stock	$36.00	$25.00
10mg	97%	in stock	$43.00	$30.00
50mg	97%	in stock	$55.00	$38.00
250mg	97%	in stock	$105.00	$74.00
1g	97%	in stock	$233.00	$163.00
5g	97%	in stock	$782.00	$547.00
25g	97%	in stock	$2,623.00	$1,836.00

Description

• Catalog Number: AB26275
• Chemical Name: 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
• CAS Number: 248281-84-7
• Molecular Formula: C19H17ClN2O3
• Molecular Weight: 356.8029
• MDL Number: MFCD08689859
• SMILES: CCN(C(=O)c1c(O)c2c(Cl)cccc2n(c1=O)C)c1ccccc1

Computed Properties

• Complexity: 571
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 3.7

Literature

• In vitro toxicity and in silico docking analysis of two novel selective AH-receptor modulators.

  Toxicology in vitro : an international journal published in association with BIBRA 20181001

• Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats.

  Toxicology and applied pharmacology 20170701

• Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.

  Journal of neuroimmunology 20121015

• Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.

  Journal of neuroimmunology 20121015

• Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.

  Acta neuropathologica 20120901

• Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.

  The American journal of pathology 20120801

• Oral laquinimod for multiple sclerosis.

  The New England journal of medicine 20120628

• Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).

  Revista de neurologia 20120616

• Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

  Bone marrow transplantation 20120601

• Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.

  Expert review of clinical pharmacology 20120501

• Drugs: An injection of hope.

  Nature 20120412

• Placebo-controlled trial of oral laquinimod for multiple sclerosis.

  The New England journal of medicine 20120315

• New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis.

  Current opinion in neurology 20120201

• Immune mechanisms of new therapeutic strategies in MS: teriflunomide.

  Clinical immunology (Orlando, Fla.) 20120101

• Laquinimod in multiple sclerosis.

  Clinical immunology (Orlando, Fla.) 20120101

• Current concepts of hyperinflammation in chronic granulomatous disease.

  Clinical & developmental immunology 20120101

• Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

  The American journal of pathology 20120101

• Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.

  Clinical & developmental immunology 20120101

• Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

  PloS one 20120101

• Immune therapy of multiple sclerosis--future strategies.

  Current pharmaceutical design 20120101

• Current therapeutic options in pediatric multiple sclerosis.

  Current treatment options in neurology 20111201

• Emerging oral drugs for relapsing-remitting multiple sclerosis.

  Expert opinion on emerging drugs 20111201

• Oral treatment for multiple sclerosis.

  The Lancet. Neurology 20111101

• Multiple sclerosis: pathogenesis and treatment.

  Current neuropharmacology 20110901

• Insight into the mechanism of laquinimod action.

  Journal of the neurological sciences 20110715

• Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial.

  Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 20110401

• Oral laquinimod treatment in multiple sclerosis.

  Neurologia (Barcelona, Spain) 20110301

• Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.

  Expert opinion on drug metabolism & toxicology 20110301

• [Current treatment of multiple sclerosis].

  Lege artis medicinae : uj magyar orvosi hirmondo 20110201

• Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

  CNS drugs 20110101

• Therapeutic approach to multiple sclerosis by novel oral drug.

  Recent patents on inflammation & allergy drug discovery 20110101

• Multiple sclerosis therapeutic pipeline: opportunities and challenges.

  The Mount Sinai journal of medicine, New York 20110101

• Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.

  Patient preference and adherence 20110101

• Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis.

  Core evidence 20110101

• Development of oral immunomodulatory agents in the management of multiple sclerosis.

  Drug design, development and therapy 20110101

• The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease.

  Parkinson's disease 20110101

• The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials.

  PloS one 20110101

• Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.

  ASN neuro 20110101

• Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.

  BMC neurology 20110101

• Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20101101

• Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.

  Journal of neuroimmunology 20101008

• Current and future role of interferon beta in the therapy of multiple sclerosis.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20101001

• Emerging therapies in relapsing-remitting multiple sclerosis.

  Reviews on recent clinical trials 20100901

• Treatment options for multiple sclerosis: current and emerging therapies.

  Pharmacotherapy 20100901

• Emerging oral agents for multiple sclerosis.

  The American journal of managed care 20100901

• Will the newer oral MS agents be welcomed by managed care organizations?

  The American journal of managed care 20100901

• New drug therapies for multiple sclerosis.

  Current opinion in neurology 20100601

• Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.

  Current opinion in investigational drugs (London, England : 2000) 20100501

• Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.

  Journal of neuroimmunology 20100415

• Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments.

  Journal of pharmacy practice 20100401

• Emerging multiple sclerosis oral therapies.

  Neurology 20100105

• A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells.

  PloS one 20100101

• Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

  Patient preference and adherence 20100101

• Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.

  Therapeutics and clinical risk management 20100101

• Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

  Drug design, development and therapy 20100101

• Multiple sclerosis therapies: molecular mechanisms and future.

  Results and problems in cell differentiation 20100101

• Disease-modifying therapies in relapsing-remitting multiple sclerosis.

  Neuropsychiatric disease and treatment 20100101

• Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets.

  Therapeutics and clinical risk management 20100101

• New approaches in the management of multiple sclerosis.

  Drug design, development and therapy 20100101

• Emerging therapies for treatment of multiple sclerosis.

  Journal of inflammation research 20100101

• The future of multiple sclerosis therapy.

  Pharmacological research 20091001

• New oral drugs for multiple sclerosis.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20091001

• Oral laquinimod therapy in relapsing multiple sclerosis.

  Expert opinion on investigational drugs 20090701

• Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides.

  PLoS biology 20090401

• Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.

  Central nervous system agents in medicinal chemistry 20090301

• Review of teriflunomide and its potential in the treatment of multiple sclerosis.

  Neuropsychiatric disease and treatment 20090101

• Recent developments in multiple sclerosis therapeutics.

  BMC medicine 20090101

• Promising treatments of tomorrow for multiple sclerosis.

  Annals of Indian Academy of Neurology 20090101

• New oral disease-modifying therapies for multiple sclerosis.

  F1000 medicine reports 20090101

• Kynurenine pathway metabolites in humans: disease and healthy States.

  International journal of tryptophan research : IJTR 20090101

• Identification and development of new therapeutics for multiple sclerosis.

  Trends in pharmacological sciences 20081101

• Emerging oral drugs for multiple sclerosis.

  Expert opinion on emerging drugs 20080901

• Oral laquinimod for treatment of relapsing-remitting multiple sclerosis.

  The Lancet. Neurology 20080801

• Laquinimod, a new oral drug for multiple sclerosis.

  Lancet (London, England) 20080621

• Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

  Lancet (London, England) 20080621

• Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model.

  International journal of biological sciences 20080101

• Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

  Drugs 20080101

• Novel oral agents for multiple sclerosis.

  Current neurology and neuroscience reports 20070501

• Oral disease-modifying treatments for multiple sclerosis: the story so far.

  CNS drugs 20070101

• Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice.

  Journal of neuroimmunology 20060401

• Synthesis and reactivity of laquinimod, a quinoline-3-carboxamide: intramolecular transfer of the enol proton to a nitrogen atom as a plausible mechanism for ketene formation.

  The Journal of organic chemistry 20060217

• Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling.

  Rapid communications in mass spectrometry : RCM 20060101

• Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.

  Drug metabolism and disposition: the biological fate of chemicals 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

  Neurology 20050322

• [Future possibilities of the multiple sclerosis treatment].

  Casopis lekaru ceskych 20050101

• Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.

  Journal of neuroimmunology 20041101

• Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.

  Journal of medicinal chemistry 20040408

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• Determination of laquinimod in plasma by coupled-column liquid chromatography with ultraviolet absorbance detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030305

• The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.

  Journal of neuroimmunology 20020901

• Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue.

  Neuropharmacology 20020401